Ratings by Piper Sandler (Dave Westenberg)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/17/2026 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/9/2026 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2025 | Pacific Biosciences of California | PACB | Maintain | Neutral (N/A) |
|
Details | ||
| 11/11/2025 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2025 | Myriad Genetics | MYGN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2025 | Cytek Biosciences Inc | CTKB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2025 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2025 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/15/2025 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2025 | Pacific Biosciences of California | PACB | Maintain | Neutral (N/A) |
|
Details | ||
| 8/11/2025 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/9/2025 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/21/2025 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/14/2025 | Akoya Biosciences Inc | AKYA | Maintain | Neutral (N/A) |
|
Details | ||
| 3/27/2025 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/12/2025 | Myriad Genetics | MYGN | Upgrade | Overweight (Neutral) |
9.60 (5.15) |
-46.35% | Details | |
| 3/5/2025 | Akoya Biosciences Inc | AKYA | Downgrade | Neutral (Overweight) |
1.55 (1.29) |
-16.77% | Details | |
| 3/4/2025 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2025 | Myriad Genetics | MYGN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/4/2025 | Cytek Biosciences Inc | CTKB | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2025 | Pacific Biosciences of California | PACB | Maintain | Neutral (N/A) |
|
Details | ||
| 2/10/2025 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/25/2024 | Cytek Biosciences Inc | CTKB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2024 | Akoya Biosciences Inc | AKYA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2024 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2024 | Akoya Biosciences Inc | AKYA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2024 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2024 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2024 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/30/2024 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/25/2024 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/15/2024 | Akoya Biosciences Inc | AKYA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/14/2024 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2024 | Pacific Biosciences of California | PACB | Maintain | Neutral (N/A) |
|
Details | ||
| 5/13/2024 | Cytek Biosciences Inc | CTKB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2024 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2024 | Cytek Biosciences Inc | CTKB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2023 | Pacific Biosciences of California | PACB | Maintain | Neutral (N/A) |
|
Details | ||
| 10/16/2023 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2023 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2023 | Cytek Biosciences Inc | CTKB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2023 | Akoya Biosciences Inc | AKYA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2023 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2023 | Pacific Biosciences of California | PACB | Maintain | Neutral (N/A) |
|
Details | ||
| 3/7/2023 | Cytek Biosciences Inc | CTKB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2022 | OncoCyte Corp | OCX | Downgrade | Neutral (Overweight) |
0.43 (3.20) |
644.19% | Details | |
| 11/14/2022 | OncoCyte Corp | OCX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2022 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2022 | Heska Corp. | HSKA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2022 | Cytek Biosciences Inc | CTKB | Maintain | Overweight (N/A) |
|
Details | ||
| 8/22/2022 | Pacific Biosciences of California | PACB | Maintain | Neutral (N/A) |
|
Details | ||
| 8/17/2022 | Heska Corp. | HSKA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/1/2022 | Heska Corp. | HSKA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/21/2022 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2022 | OncoCyte Corp | OCX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2022 | Heska Corp. | HSKA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2022 | Akoya Biosciences Inc | AKYA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2022 | Pacific Biosciences of California | PACB | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2022 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2022 | Cytek Biosciences Inc | CTKB | Maintain | Overweight (N/A) |
|
Details | ||
| 2/15/2022 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2022 | Natera | NTRA | New Coverage | Overweight (N/A) |
88.04 (198.13) |
125.05% | Details | |
| 1/6/2022 | Pacific Biosciences of California | PACB | New Coverage | Neutral (N/A) |
18.98 (1.38) |
-92.73% | Details | |
| 1/6/2022 | OncoCyte Corp | OCX | New Coverage | Overweight (N/A) |
2.20 (3.20) |
45.45% | Details | |
| 1/6/2022 | Illumina | ILMN | New Coverage | Overweight (N/A) |
372.36 (124.62) |
-66.53% | Details | |
| 1/6/2022 | Heska Corp. | HSKA | New Coverage | Overweight (N/A) |
160.77 (119.99) |
-25.37% | Details | |
| 1/6/2022 | Cytek Biosciences Inc | CTKB | New Coverage | Overweight (N/A) |
16.02 (4.22) |
-73.66% | Details | |
| 1/6/2022 | Akoya Biosciences Inc | AKYA | New Coverage | Overweight (N/A) |
14.15 (1.55) |
-89.05% | Details |
